News

Fierce Pharma1d
AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
Pharmabiz1h
Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware
Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...
STAT15h
Pharmalittle: We’re reading about FDA chaos delaying a rare disease drug, Merck’s U.S. investment, and more
Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...
BioSpace1d
Perioperative Keytruda Cuts Risk of Negative Events by Over 25% in Head and Neck Cancer
The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.
Does Merck Stock Have Room For Growth?
The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...
BioPharma Dive1d
New Akeso, Summit data stir debate on PD-1/VEGF drugs
Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...
Adjuvant PD-1 blockade for mismatch repair-deficient solid cancers directed by ctDNA status delivers clinical benefit
Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who ...
Applied Clinical Trials Online1d
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...